Grants for Public housing authorities - Federal

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI R01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of enhancing their original research and speeding up scientific discoveries in cancer research.

This funding opportunity provides financial support to organizations working in Zambia to improve HIV and TB prevention, care, and treatment services through innovative and sustainable quality improvement strategies.

This funding opportunity supports U.S.-based organizations in developing a centralized hub to advance the use of artificial intelligence and technology in research related to aging and Alzheimer's Disease, fostering collaboration and stakeholder engagement across multiple projects.

The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.

This grant provides access to specialized resources and expertise for researchers developing gene-based therapies for extremely rare neurological disorders, helping them prepare for regulatory submissions and advance their therapeutic projects.

This funding opportunity provides financial support to a wide range of organizations, including governments, educational institutions, and nonprofits, to strengthen public health systems and improve responses to infectious disease threats in Bangladesh.

This Notice of Funding Opportunity (NOFO) invites applications for a U54 Specialized Center (henceforth: Consortium) to provide resources, expertise, and coordination to advance innovative, high-quality research on palliative care for those with serious illness across the lifespan. This research infrastructure will encompass Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD), cancer, and other serious illnesses and populations relevant to the partnering Institutes, Centers, and Offices (ICOs). NIH currently funds many palliative care research projects across the ICOs, and there is a need for a structure to leverage synergies, coordinate efforts, develop the scientific workforce, and address remaining gaps in the field. The goals of this initiative include generating new scientific knowledge, in part through supporting pilot and exploratory studies; fostering development of early- and mid-career palliative care investigators; serving as a national platform to provide research resources and facilitate high-quality palliative care research; engaging healthcare systems and community-based organizations as research partners and settings for palliative care research; and disseminating research findings, best practices, data, and other impactful resources to the palliative care research and clinical communities. An important focus of the Consortiums work will be on facilitating research to understand and address disparities in access, quality, and use of palliative care services for health disparities populations or in underserved areas.

The "Puerto Rico Energy Resilience Fund: Resilient Communities Program" grant aims to use $1B in funding to enhance Puerto Rico's energy resilience and clean energy economy, particularly focusing on mitigating power outage impacts on low-income residents, ensuring energy reliability for healthcare services in disadvantaged communities, and supporting the growth of the clean energy workforce, through the installation of solar PV and battery storage in subsidized multi-family properties and community healthcare facilities.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P50 specialized centers to enhance their current cancer research by integrating new technologies or methods developed by the NCI Innovative Molecular Analysis Technologies program.

This funding opportunity provides financial support for research projects that implement effective treatments for opioid and stimulant use disorders, focusing on improving care systems and addressing health disparities.

This grant provides funding for researchers to conduct preclinical studies on the effects of radionuclide-based cancer therapies, aiming to improve treatment strategies and outcomes for cancer patients.

This funding opportunity is designed to establish a center that will coordinate and manage data for collaborative research on rare diseases, supporting various research consortia and engaging stakeholders to improve diagnosis and treatment.

The "Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD" grant aims to fund research that prepares for clinical trials focused on understanding and addressing the social, ethical, and behavioral barriers that prevent equal health outcomes for Alzheimer's Disease and Related Dementias (ADRD) in underserved and marginalized communities.

This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The ultimate goal of this initiative is attainment of optimal treatment and health outcomes goals in order to move towards health equity.

This grant provides financial support and resources to early-career faculty from underrepresented backgrounds in neuroscience, helping them establish independent research careers through mentorship and protected research time.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) Courses for Skills Development; and (2) Develop and implement a program to prepare nurse scientists, and scientists in aligned fields, to conduct research on the social determinants of health in alignment with the NINR Strategic Plan.

The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids.Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.

This funding opportunity supports research aimed at understanding how beliefs about cancer treatment outcomes influence symptom management, particularly focusing on underrepresented populations in biomedical research.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.

This program provides financial and technical support to private landowners and various organizations for habitat restoration projects that benefit fish and wildlife, particularly focusing on endangered species and climate resilience.